eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | metabolic syndrome x |
| Symptom | C0242339|dyslipidaemia |
| Sentences | 9 |
| PubMedID- 22082322 | Anacetrapib is a cholesteryl-ester-transfer-protein (cetp) inhibitor, a new class of experimental drugs in the treatment of primary hypercholesterolemia and dyslipidaemia associated with the metabolic syndrome. |
| PubMedID- 21779871 | Ultimately, the resulting hyperglycaemia and dyslipidaemia contribute to development of the metabolic syndrome complications such as cardiovascular disease and diabetic nephropathy. |
| PubMedID- 24455467 | As all our patients had dyslipidaemia characteristic of the metabolic syndrome it is reasonable to speculate that improvements in nafld/nash may have contributed to improving lft. |
| PubMedID- 19917068 | We have recently established that the jcr:la-cp rodent model develops postprandial dyslipidaemia concomitant with complications of the metabolic syndrome. |
| PubMedID- 23167714 | Bioactive phytochemicals play an important therapeutic role in attenuating oxidative damage induced by metabolic syndrome associated with atherogenic dyslipidaemia and a pro-inflammatory, pro-thrombotic state, at a sub-cellular level. |
| PubMedID- 24127654 | Obesity, diabetes mellitus (dm), and dyslipidaemia, common components of the metabolic syndrome (mets), are frequently associated with nafld; 75-100% of patients with mets or dm have nafld. |
| PubMedID- 22548055 | dyslipidaemia associated with the metabolic syndrome, including increased triglycerides and ldl and decreased hdl, is also associated with increased prostate cancer risk , and cholesterol-lowering medications such as statins are currently believed to exert most of their positive effects via systemic reductions in total cholesterol . |
| PubMedID- 26081491 | Where fasting bloods were obtained (n=78), dyslipidaemia was 56.4% with the metabolic syndrome (ms) present in 26%. |
| PubMedID- 23208524 | Nafld may represent the hepatic manifestation of the metabolic syndrome with visceral obesity, dyslipidaemia, and insulin resistance . |
Page: 1